Scott L Butler

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy
    Scott L Butler
    Infectious Diseases Group, Pfizer Global Research and Development, Sandwich, United Kingdom
    J Acquir Immune Defic Syndr 58:297-303. 2011
  2. ncbi Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors
    Michael B Plewe
    Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, USA
    J Med Chem 52:7211-9. 2009
  3. ncbi A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41
    Edward J Murray
    Antiviral Research Unit, IPC 424, Pfizer PGRD, Discovery Biology, Sandwich Laboratories, Sandwich, Kent CT13 9NJ, United Kingdom
    J Virol 84:7288-99. 2010
  4. ncbi Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors
    TED W JOHNSON
    Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States
    J Med Chem 54:3393-417. 2011

Detail Information

Publications4

  1. ncbi Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy
    Scott L Butler
    Infectious Diseases Group, Pfizer Global Research and Development, Sandwich, United Kingdom
    J Acquir Immune Defic Syndr 58:297-303. 2011
    ....
  2. ncbi Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors
    Michael B Plewe
    Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, USA
    J Med Chem 52:7211-9. 2009
    ..Several 4-fluorobenzyl substituted azaindole hydroxamic acids showed potent antiviral activities in cell-based assays and offered a structurally simple scaffold for the development of novel HIV-1 IN inhibitors...
  3. ncbi A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41
    Edward J Murray
    Antiviral Research Unit, IPC 424, Pfizer PGRD, Discovery Biology, Sandwich Laboratories, Sandwich, Kent CT13 9NJ, United Kingdom
    J Virol 84:7288-99. 2010
    ..The results highlight PF-68742 as a starting point for novel therapies against HIV-1 and provide new insights into models of Env-mediated fusion...
  4. ncbi Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors
    TED W JOHNSON
    Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States
    J Med Chem 54:3393-417. 2011
    ..Here we disclose the design and synthesis of novel tricyclic N-hydroxy-dihydronaphthyridinones as potent, orally bioavailable HIV-1 integrase inhibitors displaying excellent ligand and lipophilic efficiencies...